COMP <GO>
DARE vs ALLR // EV/EBITDA & P/E VALUATION
Dare Bioscience Inc. (NASDAQ) VS. Allarity Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DARE 2
— ALLR 1
■ METRIC PARITY
LAST: $0.68 (+0.22%) • MKT CAP: $13.4M
valuation
—
LAST: $0.89 (-6.32%) • MKT CAP: $14.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DARE VS. ALLR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DARE | ALLR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | DARE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.9 | 38.9 | +4.03 | DARE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $13.4M | $14.2M | -$756.1K | ALLR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DARE REV | ALLR REV | DARE GROSS % | ALLR GROSS % | DARE FCF | ALLR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.0M | $0 | 71.3% | — | -$10.3M | -$14.8M |
| FY 2024 | $9.8K | $0 | 98.0% | — | $4.9M | -$17.6M |
| FY 2023 | $2.8M | $0 | — | — | -$38.9M | -$12.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DARE // BETA —
ALLR // BETA —